Sign inJoin waitlistJoin the waitlist

Bart Scott

Professor, Transplantation Program, Clinical Research Division, Fred Hutch · University of Washington School of Medicine

Credentials: · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of Washington-Seattle Campus
1999–2002
Johns Hopkins University School of Medicine
1996–1999
University of South Alabama College of Medicine
1992–1996

Research

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Journal of Clinical Oncology · 2017 · First of 20 authors · 562 citations
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
Journal of Clinical Oncology · 2020 · 389 citations
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell…
Journal of Clinical Oncology · 2007 · 320 citations

Joachim Deeg
55 papers
EE
Elihu Estey
23 papers
Frederick Appelbaum
23 papers
Brenda Sandmaier
21 papers
Roland Walter
21 papers
Pamela Becker
20 papers
Rachel Salit
20 papers
PH
Paul Hendrie
19 papers
Wael Saber
19 papers
Ryotaro Nakamura
16 papers
Aaron Gerds
15 papers · 3 as a fellow
Anna Halpern
15 papers

Grants

Improving Allogenic Transplant Outcomes in Myeloid Malignancies
National Heart, Lung, and Blood Institute · K23
Contact PI · $682.4K · Fred Hutchinson Cancer Research Center
2007–2012

Clinical trials

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Principal investigator · Unknown · Phase 1
Jasper Therapeutics, Inc.
2020–2023
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
Principal investigator · Terminated · Phase 2
Fred Hutchinson Cancer Center
2017–2018
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Principal investigator · Completed · Phase 2
Fred Hutchinson Cancer Center
2013–2022
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
Principal investigator · Completed · Phase 2
Fred Hutchinson Cancer Center
2010